Objective To analyze the effect of linagliptin on the endoplasmic reticulum stress index and the incidence of cardiovascular events in patients with coronary heart disease and diabetes. Methods From March 2021 to April 2024, we identified 102 patients with coronary heart disease and diabetes for a retrospective study. They were allocated into two groups based on treatment protocols: the study group (n=52) receiving conventional therapy plus linagliptin, and the control group (n=50) on standard care. Cardiac function parameters (LVEF, SV, LVEDd) were assessed pre- and post-intervention at 3 months. Serum endoplasmic reticulum stress markers (GRP78, Caspase-12, CHOP) were compared after 3 months. Pearson correlation was used to evaluate the relationship between serum GRP78, CHOP, Caspase-12 levels, and LVEF at this time point. Results Post-intervention, both the study and control groups exhibited enhanced LVEF and SV, alongside a reduction in LVEDd. Notably, the study group demonstrated a more favorable recovery in cardiac function, though this was not statistically significant compared to the control. Following sitagliptin treatment, the study group saw a significant decline in endoplasmic reticulum stress markers GRP78, CHOP, and Caspase-12 compared to the control. Pearson correlation revealed that in the study group, serum levels of GRP78 (r=-0.678, P<0.05), CHOP (r=-0.679, P<0.05), and Caspase-12 (r=0.555, P<0.05) were inversely associated with LVEF. In contrast, the control group did not exhibit a significant correlation between these serum markers and LVEF. Conclusion Lipagliptin therapy diminishes the ER stress response in coronary heart disease and diabetic patients without notably affecting cardiovascular incidents.
Key words
ligliptin /
type 2 diabetes with coronary heart disease /
endoplasmic reticulum stress /
cardiovascular events
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 杨晨, 郭志荣, 胡晓抒, 等. 代谢综合征合并糖尿病与心血管疾病关系[J]. 中国公共卫生, 2013, 29(11): 1603-1606.
[2] 李赞, 刘喜洋, 贺卓佳, 等.1999-2019年中国糖尿病疾病负担的调查研究[J]. 解放军医学杂志, 2024, 49(7): 776-782.
[3] LEE JH, LEE J. Endoplasmic Reticulum (ER) Stress and Its Role in Pancreatic β-Cell Dysfunction and Senescence in Type 2 Diabetes[J]. Int J Mol Sci, 2022, 23(9): 4843.
[4] 谭飞龙, 刘旭. 新型降糖药物利格列汀的研究进展[J]. 国际药学研究杂志, 2013, 40(3): 286-290, 294.
[5] QASEEM A, OBLEY AJ, SHAMLIYAN T, et al.Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians[J]. Ann Intern Med, 2024, 177(5): 658-666.
[6] 虞睿琪, 肖新华. 中国老年糖尿病诊疗指南(2024版)解读[J]. 内科急危重症杂志, 2024, 30(4): 294-296.
[7] 中华医学会内分泌学分. 中国成人2型糖尿病患者动脉粥样硬化性脑心血管疾病分级预防指南[J]. 糖尿病天地(临床), 2016, 10(12): 531-536.
[8] SAHAY RK, GIRI R, SHEMBALKAR JV, et al.Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations[J]. Adv Ther, 2023, 40(7): 3227-3246.
[9] 杨坤, 刘英超, 刘艳会. 妊娠期糖尿病患者中内质网应激标志物与胎盘功能障碍的相关性研究[J]. 湖南师范大学学报(医学版), 2024, 21(3): 120-125.
[10] 雷丽冉, 付雅馨, 刘泉, 等. 内质网应激致肠-胰轴功能紊乱在2型糖尿病中的研究进展[J]. 药学学报, 2024, 59(12): 3189-3198.
[11] 顾悦, 申宇航, 丁鑫, 等. 基于PERK/ATF4/CHOP途径探讨当归补血汤含药血清抑制糖尿病肾病内质网应激改善足细胞凋亡的机制[J]. 中国实验方剂学杂志, 2024, 30(16): 10-18.
[12] MURATA N, NISHIMURA K, HARADA N, et al.Insulin reduces endoplasmic reticulum stress-induced apoptosis by decreasing mitochondrial hyperpolarization and caspase-12 in INS-1 pancreatic β-cells[J]. Physiol Rep, 2024, 12(12): e16106.
[13] 兰晋杰, 张海生. 内质网应激相关信号通路在胰岛素抵抗中的作用[J]. 中国医药科学, 2024, 14(16): 22-25, 63.
[14] LI RONG, SONG LIHUA, LIU JIE, et al.Cardioprotective effect of Linagliptin on diabetic Wistar rats[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(4): 334-346.
[15] PÉREZ-BELMONTE LM, OSUNA-SÁNCHEZ J, RICO-ROBLES JI, et al. Simplified glycaemic management for patients with type 2 diabetes admitted for acute decompensated heart failure using linagliptin[J]. Med Clin (Barc), 2022, 25;158(4): 173-177.
[16] ROSENSTOCK J, PERKOVIC V, JOHANSEN OE, et al.Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial[J]. JAMA, 2019, 321(1): 69-79.
[17] SCIRICA BM, BHATT DL, BRAUNWALD E, et al.Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J]. N Engl J Med, 2013, 369(14): 1317-1326.
[18] 吉登仁, 齐永芬. 内质网应激与心血管疾病关系的研究进展[J]. 生理学报, 2020, 72(2): 190-204.
PDF(2178 KB)
